BioSpace News Archive

INVO Bioscience, Inc. (OTCQB: INVO), (“the Company”, “INVO”) a medical device company focused on creating alternative treatments for patients diagnosed with infertility and developers of INVOcell®, the world’s only in vivo Intravaginal Culture System,

Saudi-based pharmacy chain automates its treasury and payment systems, boosting efficiency and visibility as it plans regional expansion

EyeLock LLC, the leader of iris-based identity authentication solutions, announced today that is has secured a global partnership with Integral Technology Solutions out of Freehold, New Jersey

MedLever is pleased to announce the release of a new solution built on the MedLever Platform™ for workflow automation and interoperability.

According to Coherent Market Insights, the global digital microscopes market is estimated to be valued at US$ 1,124.0 million in 2020, and is expected to exhibit a CAGR of 6.5% during the forecast period (2020-2027).

Strategic Vaccines, LLC has signed a Memorandum of Understanding with the Texas A&M Center for Innovation in Advanced Development and Manufacturing to establish a FlowVax vaccine platform manufacturing center at Texas A&M’s College Station to rapidly respond to emerging viral threats.

Derm-Biome Pharmaceuticals, Inc, a Vancouver based preclinical biopharmaceutical company focused on skin diseases and healthy ageing, is pleased to announce that it has raised $500,000 in pre-seed funding, monies that will allow it to advance its anti-aging (skin rejuvenation) and atopic dermatitis topicals to the clinic by Q1 2021.

Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (NASDAQ: VRCA). Investors who purchased Verrica securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s si

Camargo Pharmaceutical Services, LLC, congratulates Chiasma, Inc. on obtaining approval from the US Food and Drug Administration for MYCAPSSA® (octreotide) capsules. MYCAPSSA is the first and only oral somatostatin analog (SSA) approved by the FDA.

In lieu of an in-person update to the media, Dr. Theresa Tam, Canada’s Chief Public Health Officer, issued the following statement :.